Icotinib (Conmana)
General information
Class/mechanism from the NCI Drug Dictionary: An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in NMPA indication
- 2011-06-07: Initial approval for non-small cell lung cancer. (Based on ICOGEN)
- 2021-06: Approved for the postoperative adjuvant treatment of early-stage lung cancer with EGFR mutation. (Based on EVIDENCE)
Also known as
- Code name: BPI-2009H
- Brand name: Conmana